A Comparison of RML Prion Inactivation Efficiency by Heterogeneous and Homogeneous Photocatalysis.

RML prion TiO2 photocatalysis heterogeneous photocatalysis homogeneous photocatalysis photo-Fenton reagent prion decontamination prion inactivation

Journal

Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317

Informations de publication

Date de publication:
16 May 2024
Historique:
received: 03 04 2024
revised: 10 05 2024
accepted: 11 05 2024
medline: 24 5 2024
pubmed: 24 5 2024
entrez: 24 5 2024
Statut: epublish

Résumé

Prions are proteinaceous pathogens responsible for a variety of devastating diseases in mammals, including scrapie in sheep and goats, chronic wasting disease in cervids, and Creutzfeldt-Jakob disease (CJD) in humans. They are characterized by their exceptional persistence to common inactivation procedures. This applies to all possible sources of prion contamination as prions may be present in the tissues and biological fluids of infected individuals. Hence, efficient prion inactivation procedures are still being sought to minimize the risk of intra- or inter-species transmission. In the past, photocatalytic treatment has been proven to be capable of efficiently oxidizing and inactivating prions. In the present study, the efficacy of homogeneous photo-Fenton-based photocatalysis as well as heterogeneous photocatalysis with TiO

Identifiants

pubmed: 38787272
pii: pathogens13050420
doi: 10.3390/pathogens13050420
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, call RESEARCH-CREATE-INNOVATE
ID : T1EDK-02678

Auteurs

Ioannis Paspaltsis (I)

Laboratory of Pharmacology, Department of Pharmacy, School of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.

Eirini Kanata (E)

Laboratory of Pharmacology, Department of Pharmacy, School of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.

Sotirios Sotiriadis (S)

Laboratory of Pharmacology, Department of Pharmacy, School of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.

Susana Silva Correia (SS)

Department of Neurology, University Medicine Goettingen, German Center for Neurodegenerative Diseases (DZNE), 37075 Göttingen, Germany.

Matthias Schmitz (M)

Department of Neurology, University Medicine Goettingen, German Center for Neurodegenerative Diseases (DZNE), 37075 Göttingen, Germany.

Inga Zerr (I)

Department of Neurology, University Medicine Goettingen, German Center for Neurodegenerative Diseases (DZNE), 37075 Göttingen, Germany.

Dimitra Dafou (D)

Department of Genetics, Development and Molecular Biology, School of Biology, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.

Konstantinos Xanthopoulos (K)

Laboratory of Pharmacology, Department of Pharmacy, School of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Centre for Research and Technology Hellas, Institute of Applied Biosciences, 57001 Thermi, Greece.

Theodoros Sklaviadis (T)

Laboratory of Pharmacology, Department of Pharmacy, School of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.

Classifications MeSH